ANTIBODIES FOR TREATING ALPHA-SYNUCLEINOPATHIES

The present disclosure provides isolated binding proteins such as humanized antibodies and antigen-binding fragments thereof that target alpha-synuclein, including multispecific isolated binding proteins that target both alpha-synuclein and insulin-like growth factor 1 receptor. Also provided are me...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, Dongin, JUNG, Jaeho, AN, Sungwon, CHOI, Min Sun, LEE, Seung-Jae, KIM, Tae Kyung, EOM, Jaehyun, AHN, Jinhyung, SUNG, Byungje, SON, Yonggyu, LEE, Sang Hoon, YOU, Weonkyoo, JUNG, Jinwon, KIM, Juhee, KIM, Yeunju, SUNG, Eunsil
Format Patent
LanguageEnglish
French
Published 17.11.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides isolated binding proteins such as humanized antibodies and antigen-binding fragments thereof that target alpha-synuclein, including multispecific isolated binding proteins that target both alpha-synuclein and insulin-like growth factor 1 receptor. Also provided are methods of using the binding proteins to treat alpha-synucleinopathies. La présente invention concerne des protéines de liaison isolées telles que des anticorps humanisés et des fragments de liaison à l'antigène de celles-ci qui ciblent l'alpha-synucléine, notamment des protéines de liaison isolées multispécifiques qui ciblent à la fois l'alpha-synucléine et le récepteur du facteur de croissance de type insuline 1. L'invention concerne également des procédés d'utilisation des protéines de liaison pour traiter des alpha-synucléinopathies.
Bibliography:Application Number: WO2022IB54445